292 related articles for article (PubMed ID: 36766711)
1. Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review.
Elvevi A; Laffusa A; Gallo C; Invernizzi P; Massironi S
Cells; 2023 Jan; 12(3):. PubMed ID: 36766711
[TBL] [Abstract][Full Text] [Related]
2. Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions.
Cossiga V; Guarino M; Capasso M; Morisco F
Cells; 2023 Jun; 12(12):. PubMed ID: 37371045
[TBL] [Abstract][Full Text] [Related]
3. Association of Chronic Opisthorchis Infestation and Microbiota Alteration on Tumorigenesis in Cholangiocarcinoma.
Ketpueak T; Thiennimitr P; Apaijai N; Chattipakorn SC; Chattipakorn N
Clin Transl Gastroenterol; 2020 Dec; 12(1):e00292. PubMed ID: 33464733
[TBL] [Abstract][Full Text] [Related]
4. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of cholangiocarcinoma carcinogenesis.
Maemura K; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
[TBL] [Abstract][Full Text] [Related]
6. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma.
Vicent S; Lieshout R; Saborowski A; Verstegen MMA; Raggi C; Recalcati S; Invernizzi P; van der Laan LJW; Alvaro D; Calvisi DF; Cardinale V
Liver Int; 2019 May; 39 Suppl 1():79-97. PubMed ID: 30851232
[TBL] [Abstract][Full Text] [Related]
7. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of Cholangiocarcinoma Immune Biology.
Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C
Cells; 2023 Mar; 12(6):. PubMed ID: 36980187
[TBL] [Abstract][Full Text] [Related]
9. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
10. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.
Liu R; Zhao R; Zhou X; Liang X; Campbell DJ; Zhang X; Zhang L; Shi R; Wang G; Pandak WM; Sirica AE; Hylemon PB; Zhou H
Hepatology; 2014 Sep; 60(3):908-18. PubMed ID: 24700501
[TBL] [Abstract][Full Text] [Related]
11. Circular RNAs in cholangiocarcinoma.
Liao W; Feng Q; Liu H; Du J; Chen X; Zeng Y
Cancer Lett; 2023 Jan; 553():215980. PubMed ID: 36336149
[TBL] [Abstract][Full Text] [Related]
12. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
13. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.
Raggi C; Invernizzi P; Andersen JB
J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250
[TBL] [Abstract][Full Text] [Related]
14. Pathologic classification of cholangiocarcinoma: New concepts.
Nakanuma Y; Kakuda Y
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
[TBL] [Abstract][Full Text] [Related]
15. New challenges in cholangiocarcinoma candidates for elective surgery: harnessing the microbiome dysbiosis.
Re OL; López-López V; Balaguer-Román A; Martínez-Sánchez MA; Eshmuminov D; Llamoza-Torres CJ; Miura K; Baroja-Mazo A; Ramírez P; Robles-Campos R; Ramos-Molina B
Langenbecks Arch Surg; 2023 Mar; 408(1):134. PubMed ID: 37000331
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of cholangiocarcinoma.
Rizvi S; Gores GJ
Dig Dis; 2014; 32(5):564-9. PubMed ID: 25034289
[TBL] [Abstract][Full Text] [Related]
17. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
18. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
19. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.
Nakagawa H; Hayata Y; Yamada T; Kawamura S; Suzuki N; Koike K
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29895797
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
